

116TH CONGRESS 1ST SESSION

H. R. 2428

To amend title XXVII of the Public Health Service Act to prohibit group health plans and health insurance issuers offering group or individual health insurance coverage from imposing cost-sharing requirements or treatment limitations with respect to diagnostic examinations for breast cancer that are less favorable than such requirements with respect to screening examinations for breast cancer.

IN THE HOUSE OF REPRESENTATIVES

May 1, 2019

Mrs. DINGELL (for herself, Mr. KING of New York, Ms. WASSERMAN SCHULTZ, Mr. FITZPATRICK, Mr. ALLRED, and Mrs. RODGERS of Washington) introduced the following bill; which was referred to the Committee on Energy and Commerce

A BILL

To amend title XXVII of the Public Health Service Act to prohibit group health plans and health insurance issuers offering group or individual health insurance coverage from imposing cost-sharing requirements or treatment limitations with respect to diagnostic examinations for breast cancer that are less favorable than such requirements with respect to screening examinations for breast cancer.

- 1 Be it enacted by the Senate and House of Representa-
- 2 tives of the United States of America in Congress assembled,

1 SECTION 1. SHORT TITLE.

2	This Act may be cited as the "Access to Breast Can-
3	cer Diagnosis Act of 2019".
4	SEC. 2. REQUIRING PARITY IN COST-SHARING AND TREAT-
5	MENT LIMITATIONS WITH RESPECT TO DIAG-
6	NOSTIC AND SCREENING EXAMINATIONS FOR
7	BREAST CANCER.
8	(a) In General.—Section 2719A of the Public
9	Health Service Act (42 U.S.C. 300gg-19a) is amended by
10	adding at the end the following new subsection:
11	"(e) Diagnostic and Screening Examinations
12	FOR BREAST CANCER PARITY.—
13	"(1) IN GENERAL.—In the case of a group
14	health plan, or a health insurance issuer offering
15	group or individual health insurance coverage, that
16	provides benefits with respect to a diagnostic exam-
17	ination for breast cancer furnished to an individual
18	enrolled under such plan or such coverage, such plan
19	or such coverage shall ensure that—
20	"(A) the cost-sharing requirements appli-
21	cable to such examination for such individual
22	are no less favorable than such requirements
23	applicable to a screening examination for breast
24	cancer for such individual; and
25	"(B) the treatment limitations applicable
26	to such diagnostic examination for breast can-

1	cer for such individual are no less favorable
2	than such limitations applicable to a screening
3	examinations for breast cancer for such indi-
4	vidual.
5	"(2) Restriction on Certain Changes.—A
6	group health plan or health insurance issuer may
7	not, for the sole purpose of complying with para-
8	graph (1), increase cost-sharing requirements with
9	respect to screening examinations for breast cancer.
10	"(3) Construction.—Nothing in this sub-
11	section shall be construed—
12	"(A) to require the use of diagnostic ex-
13	aminations for breast cancer as a replacement
14	for screening examinations for breast cancer;
15	"(B) to prohibit a group health plan or
16	health insurance issuers from requiring prior
17	authorization or imposing other appropriate uti-
18	lization controls in approving coverage for any
19	screening or diagnostic imaging; or
20	"(C) to supersede a State law that pro-
21	vides greater protections with respect to the
22	coverage of diagnostic examinations for breast
23	cancer than is provided under this subsection.
24	"(4) Definitions.—In this subsection:

1	"(A) Cost-sharing requirement.—The
2	term 'cost-sharing requirement' includes a de-
3	ductible, coinsurance, copayment, and any max-
4	imum limitation on the application of such a
5	deductible, coinsurance, copayment, or similar
6	out-of-pocket expense.
7	"(B) Diagnostic examination for
8	BREAST CANCER.—The term 'diagnostic exam-
9	ination for breast cancer' means a medically
10	necessary and appropriate (as determined by
11	the health care professional treating the indi-
12	vidual) examination for breast cancer to evalu-
13	ate an abnormality in the breast that is—
14	"(i) seen or suspected from a screen-
15	ing examination for breast cancer;
16	"(ii) detected by another means of ex-
17	amination; or
18	"(iii) suspected based on the medical
19	history or family medical history of the in-
20	dividual.
21	"(C) Examination for Breast can-
22	CER.—The term 'examination for breast cancer'
23	includes such an examination using breast
24	ultrasound, breast magnetic resonance imaging,
25	or mammography.

1	"(D) TREATMENT LIMITATION.—The term
2	'treatment limitation' includes limits on the fre-
3	quency of treatment, number of visits, days of
4	coverage, or other similar limits on the scope or
5	duration of treatment.".
6	(b) Application to Grandfathered Health
7	Plans.—Section 1251(a)(4)(A) of the Patient Protection
8	and Affordable Care Act (42 U.S.C. $18011(a)(4)(A)$) is
9	amended—
10	(1) by striking "title" and inserting "title, or as
11	added after the date of the enactment of this Act)";
12	and
13	(2) by adding at the end the following new
14	clause:
15	"(v) Section 2719A(e) (relating to
16	parity for diagnostic and screening exami-
17	nations for breast cancer).".
18	(e) Effective Date.—The amendments made by
19	this section shall apply with respect to plan years begin-
20	ning on or after January 1, 2020.

 \bigcirc